Cancer pain Signs and Symptoms Pain, not elsewhere classified
Conditions
Interventions
Patients are randomised to one of two treatment arms:
1. Arm A: Durogesic (transdermal fentanyl) commencing at 25 µg/h with rescue analgesia as needed.
2. Arm B: Sustai
Sponsors
Janssen-Cilag Ltd (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years old 2. Histologically, radiologically or haematologically confirmed malignancy, whose pain is judged by the investigator to be caused by the malignancy 3. Patients whose pain has reached a stage now requiring treatment with a strong opioid 4. Patients who have received a regular weak opioid, for at least 48 hours and at a dosage appropriate for their pain at that time 5. Not previously received regular treatment with a strong opioid for their cancer pain. This should have not exceeded more than three doses of a strong immediate release opioid in the last 7 days, and none in the last 24 h 6. No planned treatment within the next 24 h which may alter abruptly the degree or nature of pain experienced 7. No current or planned cytotoxic chemotherapy 8. No medical contraindications to protocol treatment
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed